B Aleiri et al. JPGN 2023; 77: 97-102. Matrix Metalloproteinase-7 and Osteopontin Serum Levels as Biomarkers for Biliary Atresia

In this study, serum was assessed from 32 biliary atresia (BA) patients and 27 controls.

Key findings:

• Median MMP-7 was higher in BA (96.4 vs 35 ng/mL; P < 0.0001) with an optimal cut-off value of 69 ng/mL. Sensitivity and specificity was 68% and 93%, respectively [negative predictive value (NPV) = 71%]
• Median osteopontin (OPN) was higher in BA (1952 vs 1457 ng/mL; P = 0.0001) and an optimal cut-off of 1611 ng/mL. Sensitivity and specificity was 84% and 78%, respectively (NPV = 81%)

The authors note that numerous studies from Asian countries have shown very high sensitivity and specificity for MMP-7. These studies used different cut-offs based on the testing kit. One limitation of this study was that samples were stored for a median of 12 years and perhaps this affected the results (some prior studies also used banked specimens).

My take: When these levels are very elevated, they are highly suggestive of BA. This study serves as a caution to note that the sensitivity at typical cut off values could be suboptimal

Related blog posts:

• MMP-7 Helps Sort Out Biliary Atresia from Parenteral Nutrition-Associated Liver Disease
• More Data, More Nuance with MMP-7: Best Biliary Atresia Biomarker
• Dried Blood Spot Testing for Biliary Atresia
• Online Aspen Webinar (Part 5) -Biliary Atresia Diagnosis and Screening (2020)
• Biliary Atresia Biomarkers 2020
• How To Diagnose Biliary Atresia in 48 hrs
• New Way to Diagnose Biliary Atresia
• Blood Test is Better Than a Liver Biopsy for Biliary Atresia